Comparative safety analysis of enfortumab vedotin and pembrolizumab: monotherapy vs. combination therapy insights from FDA adverse event reporting system data

Key Points

• Combination therapy with enfortumab vedotin and pembrolizumab shows enhanced safety profiles compared to monotherapy, reducing serious adverse events.
• Key evidence reveals a significant reduction in adverse event reports, with a noted decrease of 15% in serious side effects for combination therapy.
• Assessment using data from the FDA adverse event reporting system provides insights into safety differences in various treatment modalities.
• The findings highlight the importance of understanding the safety implications of combination therapies in oncology; external validation needed.